Misplaced Pages

Gene therapy for blood diseases

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Blood that has been modified for therapeutic or other purposes
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (March 2016)

Gene therapy for blood diseases is a novel field of research investigating ways in which components of blood can be genetically modified to treat hematologic diseases.

Current clinical applications

CAR-T therapy targeting leukemia

A diagram depicting CAR T-cell therapy from the National Cancer Institute (NCI)

Source:

CAR T-cell therapy is a type of personalized cancer immunotherapy designed to strengthen the patient’s own immune system to better fight cancer. The process begins by extracting T-cells, a type of immune cell, from an individual patient’s blood. The surface of cancer cells contains unique markers called antigens. The patient’s T-cells are genetically modified in laboratories to include chimeric antigen receptors (CARs). The CARs are designed to recognize the specific cancer antigens and bind to them, allowing T-cells to target and attack the cancer cells. The genetically modified T-cells are administered back to the patients as a treatment.

Leukemia is a group of blood cancers commonly found in children younger than 15 and elders older than 55. In 2017, tisagenlecleucel (Kymriah™), the first CAR-T cell therapy approved by the FDA, became available to anyone up to the age of 25 with acute lymphoblastic leukemia (ALL). Until 2022, a total of six CAR-T therapies have been approved by the FDA, all of which target blood cancers. These CAR-T therapies have been shown to have high efficacy in eradicating leukemia cancer, including in patients with advanced-stage, treatment-resistant (refractory) or returned (relapsed) leukemia. They also have a high remission rate in comparison to other traditional cancer treatments.

Hematopoietic stem cell therapy targeting sickle cell disease

Comparison between healthy red blood cells and red blood cells in an individual with sickle cell anemia.

Patients in the U.S. suffering from sickle cell disease can now receive targeted gene therapies using hematopoietic stem cells. Hematopoietic stem cells are stem cells which differentiate and give rise to red blood cells, white blood cells and platelets. These therapies involve removing hematopoietic stem cells from the patient and making specific edits to the genome of the hematopoietic stem cells. These edits in the genome of the hematopoietic stem cells are to reverse the effects of sickle cell disease. The cells are then re-administered into the patient. The hematopoietic stem cells are then able to produce red blood cells with the factors which promote proper red blood cell shape reducing the effects of sickle cell disease.

Gene editing therapy for Beta thalassemia

Beta thalassemia is a heritable disorder, characterized by the inability to make beta globin protein, and in turn reduced functioning of hemoglobin (which beta globin is a part of). In December 2023, the European Medicines Agency recommended approval for a cell based gene therapy that works through the CRISPR/Cas9 system. The therapy known as Casgevy works through editing a dysfunctional protein that interferes with creation of adult hemoglobin. This gene is known as the BCL11A, and when people have Beta thalassemia, their bodies do not make enough adult hemoglobin. Casgevy uses precise gene editing of stem cells, and reduces the activity of BCL11A. With the subsequent reduction of adult hemoglobin, fetal hemoglobin (HbF) genes are turned back on, allowing the cells to produce enough hemoglobin. Typically, the body stops making fetal hemoglobin around 6 months of age, and starts making adult hemoglobin. These serve similar functions, however fetal hemoglobin has a higher binding affinity for oxygen than adult hemoglobin, but both are functional at transporting oxygen in the body. Stem cells edited by Casgevy are then transfused back into the body where they can create more HbF and therefore make more functional red blood cells that have this edit. With this therapy, patients who would regularly need blood transfusions can now produce enough hemoglobin for themselves.

Genome editing for HIV resistance

Human immunodeficiency virus (HIV) is a disease that, once contacted, attacks cells that are necessary to fight off infections. It can be transmitted in many different ways, including through sexual contact, blood contamination, the sharing of needles, or from mother to infant. If left untreated, HIV can result in acquired immunodeficiency syndrome (AIDS). HIV weakens an individual’s immune system, leading to increased risk of fatal infections and cancers. In 2023, around 40 million people globally were living with HIV. Despite options available for the treatment and management of HIV (e.g., highly active antiretroviral therapy; HAART), they come with limitations including the need for indefinite daily treatment. Attempts to generate a long-term HIV-resistant immune system have been promising with results from a case report of a patient who developed acute myeloid leukemia after HIV infection. Previously, researchers had found a version of a gene (an allele) that was resistant to HIV. These researchers therefore found a donor who had two copies of this allele (homozygous) and extracted their stem cells in an attempt to produce HIV resistance in the patient with acute myeloid leukemia. After stem cell transplantation from this donor, the patient tested and remained HIV-negative at 20 months post-transplantation and was able to discontinue use of antiviral therapies.

References

  1. Nienhuis, Arthur W. (2008-05-01). "Development of gene therapy for blood disorders". Blood. 111 (9): 4431–4444. doi:10.1182/blood-2007-11-078121. ISSN 0006-4971. PMID 18441245.
  2. ^ "CAR T-Cell Therapy Approved for Children, Young Adults with Leukemia - NCI". www.cancer.gov. 2017-09-11. Retrieved 2024-11-26.
  3. "Leukemia—Patient Version - NCI". www.cancer.gov. Retrieved 2024-11-26.
  4. "CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI". www.cancer.gov. 2013-12-06. Retrieved 2024-11-26.
  5. Pan, J.; Yang, J. F.; Deng, B. P.; Zhao, X. J.; Zhang, X.; Lin, Y. H.; Wu, Y. N.; Deng, Z. L.; Zhang, Y. L.; Liu, S. H.; Wu, T.; Lu, P. H.; Lu, D. P.; Chang, A. H.; Tong, C. R. (2017-05-15). "High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients". Leukemia. 31 (12): 2587–2593. doi:10.1038/leu.2017.145. ISSN 1476-5551. PMID 28490811.
  6. Commissioner, Office of the (2024-08-09). "FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease". FDA. Retrieved 2024-11-26.
  7. "Hematopoietic stem cell". www.cancer.gov. 2011-02-02. Retrieved 2024-11-26.
  8. "Beta Thalassemia". Cleveland Clinic. July 20, 2022. Retrieved Nov 25, 2024.
  9. "How CASGEVY Works". Casgevy. Retrieved Nov 25, 2024.
  10. ^ Thein, S. L.; Menzel, S.; Lathrop, M.; Garner, C. (2009-10-15). "Control of fetal hemoglobin: new insights emerging from genomics and clinical implications". Human Molecular Genetics. 18 (R2): R216 – R223. doi:10.1093/hmg/ddp401. ISSN 0964-6906. PMC 2758709. PMID 19808799.
  11. "First gene editing therapy to treat beta thalassemia and severe sickle cell disease | European Medicines Agency (EMA)". www.ema.europa.eu. 2023-12-15. Retrieved 2024-11-26.
  12. "Causes". stanfordhealthcare.org. Retrieved 2024-11-26.
  13. "What Are HIV and AIDS?". HIV.gov. Retrieved 2024-11-26.
  14. "What is HIV and AIDS?". www.pennmedicine.org. Retrieved 2024-11-26.
  15. UNAIDS. "Global HIV & AIDS statistics". UNAIDS.
  16. Porteus, Matthew H. (2015-03-01). "Genome Editing of the Blood: Opportunities and Challenges". Current Stem Cell Reports. 1 (1): 23–30. doi:10.1007/s40778-014-0003-z. ISSN 2198-7866. PMC 4444059. PMID 26029496.
  17. ^ Hütter, Gero; Nowak, Daniel; Mossner, Maximilian; Ganepola, Susanne; Müßig, Arne; Allers, Kristina; Schneider, Thomas; Hofmann, Jörg; Kücherer, Claudia; Blau, Olga; Blau, Igor W.; Hofmann, Wolf K.; Thiel, Eckhard (2009-02-12). "Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation". New England Journal of Medicine. 360 (7): 692–698. doi:10.1056/NEJMoa0802905. ISSN 0028-4793. PMID 19213682.


Stub icon

This genetics article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This article about biological engineering is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This hematology article is a stub. You can help Misplaced Pages by expanding it.

Categories: